Fig. 1
TRX1 expression increases with prostate cancer progression. a TRX1 expression in normal and tumor prostatic tissue from the indicated ONCOMINE datasets. Boxplots represent the five number distribution. The top and bottom of the box indicates the 75th and 25th percentile, respectively. The whisker represents 1.5 times the interquartile range from the box. Number of samples (n) and p-values (determined by a two-tailed Mann–Whitney U test) are as shown. b Analysis of TRX1 expression among advanced, high Gleason-scored tumors from the PCa TCGA provisional dataset, shown as median-centered distribution. The p-value was obtained through the Kruskal–Wallis overall comparison test. c The percentages of samples with TRX1 gene amplification in advanced PCa (CRPC, NEPC) or TRX1 mRNA upregulation (metastatic) from indicated cBioportal datasets. d Comparative differences in TRX1 expression among normal prostatic tissue, AD-responsive PCa, and metastatic PCa from indicated datasets. The pairwise p-values were determined by two-tailed Mann–Whitney U test. e TRX1 mRNA expression under AD in early CRPC LNCaP SB5 relative to their androgen-dependent LNCaP SB0 counterparts. Expression levels were obtained from an Illumina-based microarray analysis of mRNA isolated under androgen-replete (FBS) or androgen-deprived (CSS) culture with samples run in triplicate. The ordinate represents the fold-change in TRX1 expression in SB5 cells relative to SB0, in the indicated categories. The p-value is FDR-adjusted. f Quantitation of TRX1 protein expression from three independent western blots comparing androgen-dependent LNCaP (SB0), and its CRPC counterparts, LNCaP SB5, and LNAI cells under the indicated conditions. Fold-changes in protein expression relative to baseline (FBS) TRX1 expression per cell line are shown. Error bars represent ± SEM. The p-value was determined through a two-tailed Student’s t-test
